ImmunityBio Gets FDA Authorization for Breast-Cancer Study

By Matt Grossman

ImmunityBio Inc. has received authorization from the Food and Drug Administration to conduct a Phase 1b/2 study on whether its Anktiva drug can be an effective addition to standard chemotherapy and Trodelvy in patients with a form of breast cancer.

The study is directed at patients whose breast cancer hasn't responded to other treatments. Only a third of third-line patients respond to Trodelvy alone, and less than 17% continue to respond after a year.

The addition of Anktiva could help fill a treatment gap if it is effective, ImmunityBio Executive Chairman Patrick Soon-Shiong said. Under the planned treatment, Trodelvy would work by targeting a protein displayed by many cancer cells, while Anktiva would "recruit" a patient's immune system to continue fighting the tumor, ImmunityBio said.

The planned study will enroll a maximum of 79 subjects.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

June 15, 2021 07:30 ET (11:30 GMT)

ImmunityBio (NASDAQ:IBRX)
Historical Stock Chart
From Aug 2024 to Sep 2024